Clinical Trials Directory

Trials / Unknown

UnknownNCT06341101

Timely Recovery After Subclinical Heart Failure

Timely Recovery After Subclinical Heart Failure (TREASURE Trial)

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
130 (estimated)
Sponsor
Academisch Ziekenhuis Maastricht · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this randomized controlled trial is to assess the effectiveness of ACE inhibitors versus standard care) in reversing asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction during a two-year open-label treatment period for formerly preeclamptic women on: 1. Reversibility of structural and functional myocardial impairment in asymptomatic HF towards healthy values; 2. The progression from asymptomatic to symptomatic HF (symptoms scored based on the NYHA criteria); 3. Cardiovascular performance (volume- and pressure load), cardio metabolic risk factors (glucose metabolism, lipid status, kidney function) and quality of life (questionnaires); 4. Novel biomarkers and relevant microRNA's indicative for hypertrophy, fibrosis inflammation and ischemia. Eligible subjects will be counselled and upon informed consent randomized for either medication group (n=65) or care as usual group (n=65). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). Thereafter, standard medical check-ups (blood pressure, ECG, kidney function, transthoracic cardiac ultrasound, endothelial function, quality of life questionnaires, medical history taking, blood and urine banking) will be performed every six months for two years. Researchers will compare ACE inhibitor (Perindopril 2 mg) and care as usual (i.e. no medication) to investigate whether ACE inhibitor allows timely recovery after subclinical heart failure.

Conditions

Interventions

TypeNameDescription
DRUGPerindoprilIn case of side effects Perindopril will be replaced by Valsartan

Timeline

Start date
2024-03-26
Primary completion
2026-03-01
Completion
2026-03-01
First posted
2024-04-02
Last updated
2024-04-02

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06341101. Inclusion in this directory is not an endorsement.